Industry Supports US FDA Conformity Assessment Concept, But Questions Abound

Manufacturers and trade groups generally support an FDA plan to pilot a program that would outsource some standard-conformance certification to outside device testing labs. But companies have questions, and some are urging the agency to consider some standards it currently does not recognize to be included in the pilot.

US FDA’s plan to allow third-party certified device testing labs, instead of the agency, to sign off on a device firm's conformance to consensus standards should work if it’s properly implemented, manufacturers say, but some stakeholders worry that currently recognized consensus standards may not be sufficient to support an FDA pilot.

FDA committed to establishing an Accreditation Scheme for Conformity Assessment (ASCA) in the agency's MDUFA IV user-fee commitment letter. MDUFA IV was formally enacted into law Aug. 18 as part...

More from Regulation

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

More from Policy & Regulation